Zanolimumab

Summary

Zanolimumab (CHEMBL2108063) is a phase-3 clinical-stage antibody; indicated across 5 conditions including sezary syndrome and mycosis fungoides.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 5 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108063
Name	Zanolimumab
Type	Antibody
Max phase	3

Also known as: HuMax-CD4, Humax-cd4, MDX-016, Zanolimumab, ZANOLIMUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Sezary syndrome	3	MONDO:0017844	EFO:1000785
mycosis fungoides	3	MONDO:0009691	EFO:1001051
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
primary cutaneous T-cell non-Hodgkin lymphoma	2	MONDO:0000607	EFO:0002913
lymphoma	2	MONDO:0005062	EFO:0000574

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	3
PHASE2/PHASE3	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00042406	PHASE2/PHASE3	TERMINATED	Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker
NCT00127881	PHASE3	TERMINATED	Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
NCT00877656	PHASE2/PHASE3	COMPLETED	HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
NCT00071071	PHASE2	COMPLETED	Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
NCT00071084	PHASE2	COMPLETED	Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
NCT01160445	PHASE2	TERMINATED	Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).